Male birth control maker raises $2.5 million to develop “Plan A”
ORIGINALLY POSTED ON Axios
JANUARY 2024
Next Life Sciences has raised $2.5 million to develop a male contraceptive product called Plan A, which could become a nonsurgical alternative to vasectomies.
Why it matters: This could help balance family-planning responsibilities that fall disproportionately on women.
Zoom in: Plan A is being pitched as a medical device instead of as a drug, which Next Life Sciences CEO L.R. Fox says should reduce the time and expense of clinical trials that begin later this year.